. In key high-burden countries, such as China, India and South Africa, most new cases of drug-resistant TB arise as a consequence of direct transmission of resistant strains 2 , rather than as a result of acquisition of resistance during treatment. In these countries, the drug-resistant TB epidemic is a parallel epidemic, which will not be eradicated even if drug-susceptible TB is controlled.
guide choice of antibiotics, improves patient outcomes and minimises adverse effects. Recent years have seen substantial advances in our ability to provide rapid, detailed drugresistance profiles using genotypic methods for detection of mutations conferring drug-resistance. Rapid testing using real-time PCR to target the most important drug-resistance mutations allows the diagnosis of drug resistance to be made with the first diagnostic test, even in low resource settings. The use of whole genome sequencing to infer resistance to a range of different drugs facilitates earlier tailoring of therapy and detection of resistant subpopulations in mixed infections. Low burden countries, such as Australia are well positioned to lead the development and refinement of these new methods, to accelerate the incorporation of these new tools into TB control programs in high burden countries.
While the incidence of new tuberculosis (TB) cases is estimated to
be declining at about 2% per year worldwide, with even steeper declines in TB mortality, TB remains the leading infectious cause of death globally 1 . However, sequential surveys of drug-resistance have shown that multidrug-resistant TB (MDR-TB, resistant to the key drugs rifampicin and isoniazid) is not following a similar trend, with countries either reporting increasing rates of MDR-TB, or rates that are declining much more slowly than drug-susceptible disease 1 . In key high-burden countries, such as China, India and South Africa, most new cases of drug-resistant TB arise as a consequence of direct transmission of resistant strains 2 , rather than as a result of acquisition of resistance during treatment. In these countries, the drug-resistant TB epidemic is a parallel epidemic, which will not be eradicated even if drug-susceptible TB is controlled. TB isolates exhibit clinically relevant heterogeneity in susceptibility, not captured through culture-based drug-susceptibility testing (DST) using a single drug concentration While several 'high confidence' mutations are highly specific for resistance, others are associated with variable, or low-level resistance. Several new rapid molecular diagnostics are coming to market. The BD MAX MDR-TB assay, from Becton Dickinson, is a real-time PCR test that detects resistance to rifampicin (rpoB) and isoniazid (inhA and katG) using raw sputum or sputum sediment. It allows batch processing of 24 samples in four hours and is suitable for centralised laboratory testing 17 . Results from a multicenter diagnostic accuracy study are expected shortly. An Xpert MTB/XDR cartridge that targets katG and the inhA promoter for isoniazid, gyrA for the fluoroquinolones, and rrs for kanamycin and amikacin was also recently evaluated 18 .
In general, since they target the same genomic regions, these rapid PCR-based molecular diagnostics show similar performance characteristics for detection of resistance. Sensitivity for rifampicin resistance is typically above 95%, for isoniazid around 85%, for fluoroquinolones approximately 90% and for injectable drugs 70%.
Specificity is usually high (approximately 95%) for all of these drugs.
Choice of an assay may therefore depend on other features, such as sensitivity for TB detection, whether one is testing a sputum sample or a cultured isolate, laboratory infrastructure, workload and cost. . There is also no consensus on criteria for detection of mixed infections (with mixed populations of susceptible and resistant bacilli), and the related issue of the sequence coverage needed to detect resistant sub-populations.
At present a major limitation of WGS is that cultured isolates are required to provide sufficient pure M. tuberculosis DNA for sequencing. Growing evidence suggests that culture masks clinically relevant heterogeneity in drug resistance 28 . Methods for direct sequencing of M. tuberculosis DNA in patient specimens are being developed 29 , but these are currently insensitive and complex.
Finally, analytical and bioinformatics platforms for whole genome sequencing are best suited to large centralised laboratories, and so their applicability in low resource settings, or closer to the point of care is unclear. Several groups have explored the use of Nanopore sequencing of M. tuberculosis isolates 30 , which may be better suited to low volume, low-resource settings, with some success.
Tackling the drug-resistant TB epidemic will require rapid diagnosis 
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